Jellagen founded in 2013, is a UK Marine Biotechnologies Company based in Cardiff, whose strategic mission is to utilise sustainable marine species and natural resources, to develop technical and scientific high value products, meeting state of the art specifications. The first products developed by Jellagen are based on Next Generation Collagen extracted from Jellyfish. These products developed through this new technology, are cell culture reagents used to grow stem cells in 2D and 3D by the Biotech and Pharma Industry R&D teams.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BIOTECH LIFE SCIENCES INITIATES NEW STUDY OF ANTI-AGING FORMULAS IN HELPING COVID-19 POST-VIRAL FATIGUE AND CHRONIC FATIGUE SYNDROME

BioTech Life Sciences | August 06, 2020

news image

BioTech Life Sciences (BioTech – https://btl.science) recently announced it was studying the effects of its proprietary formulas on long-term patient symptoms related to COVID-19 Post-Viral Fatigue (long-haulers) and chronic fatigue syndrome (C.F.S.).The findings will be a part of a larger research study undertaken by the company, and is currently calling for voluntary participants; especially those who suffer from myalgic encephalomyelitis (M.E.), chronic fatigue syndrome, or Post-V...

Read More

MedTech

WITH "PRODRUGS FOR CANCER TREATMENT" PATENT, GATC HEALTH ENTERS ONCOLOGY MEDICINE MARKET

GATC Health Corp | April 22, 2022

news image

GATC Health, a biotech company that uses artificial intelligence and advanced multiomics to revolutionize drug discovery and disease prediction, announced that it filed a patent application for an innovative new prodrug designed to safely cross the blood-brain barrier (BBB) for cancer treatment. GATC Health's entry into the oncology drug discovery market is marked by this breakthrough, which was made possible by the company's innovative Multiomics Advanced TechnologyTM AI platform....

Read More

INOVIO REPORTS FDA PARTIAL CLINICAL HOLD FOR PLANNED PHASE 2 / 3 TRIAL OF COVID-19 VACCINE CANDIDATE INO-4800

INOVIO | September 28, 2020

news image

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that the U.S. Food and Drug Administration (FDA) has notified the company it has additional questions about the company's planned Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA® 2000 delivery device to be used in the trial. Until the FDA's questions have been satisfac...

Read More

Industrial Impact

AMBERSTONE BIOSCIENCES SECURES $12 MILLION SERIES A FINANCING TO ADVANCE IMMUNO-ONCOLOGY PIPELINE OF TUMOR MICROENVIRONMENT ACTIVATED THERAPEUTICS

Amberstone Biosciences, Inc. | January 04, 2022

news image

Amberstone Biosciences an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round. The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and existing shareholders. Amberstone will use the proceeds from the financing to advance its highly differentiated tumor microenviron...

Read More
news image

BIOTECH LIFE SCIENCES INITIATES NEW STUDY OF ANTI-AGING FORMULAS IN HELPING COVID-19 POST-VIRAL FATIGUE AND CHRONIC FATIGUE SYNDROME

BioTech Life Sciences | August 06, 2020

BioTech Life Sciences (BioTech – https://btl.science) recently announced it was studying the effects of its proprietary formulas on long-term patient symptoms related to COVID-19 Post-Viral Fatigue (long-haulers) and chronic fatigue syndrome (C.F.S.).The findings will be a part of a larger research study undertaken by the company, and is currently calling for voluntary participants; especially those who suffer from myalgic encephalomyelitis (M.E.), chronic fatigue syndrome, or Post-V...

Read More
news image

MedTech

WITH "PRODRUGS FOR CANCER TREATMENT" PATENT, GATC HEALTH ENTERS ONCOLOGY MEDICINE MARKET

GATC Health Corp | April 22, 2022

GATC Health, a biotech company that uses artificial intelligence and advanced multiomics to revolutionize drug discovery and disease prediction, announced that it filed a patent application for an innovative new prodrug designed to safely cross the blood-brain barrier (BBB) for cancer treatment. GATC Health's entry into the oncology drug discovery market is marked by this breakthrough, which was made possible by the company's innovative Multiomics Advanced TechnologyTM AI platform....

Read More
news image

INOVIO REPORTS FDA PARTIAL CLINICAL HOLD FOR PLANNED PHASE 2 / 3 TRIAL OF COVID-19 VACCINE CANDIDATE INO-4800

INOVIO | September 28, 2020

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that the U.S. Food and Drug Administration (FDA) has notified the company it has additional questions about the company's planned Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA® 2000 delivery device to be used in the trial. Until the FDA's questions have been satisfac...

Read More
news image

Industrial Impact

AMBERSTONE BIOSCIENCES SECURES $12 MILLION SERIES A FINANCING TO ADVANCE IMMUNO-ONCOLOGY PIPELINE OF TUMOR MICROENVIRONMENT ACTIVATED THERAPEUTICS

Amberstone Biosciences, Inc. | January 04, 2022

Amberstone Biosciences an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round. The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and existing shareholders. Amberstone will use the proceeds from the financing to advance its highly differentiated tumor microenviron...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us